Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 174

1.

Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients.

Jadoul M, Bieber BA, Martin P, Akiba T, Nwankwo C, Arduino JM, Goodkin DA, Pisoni RL.

Kidney Int. 2019 Apr;95(4):939-947. doi: 10.1016/j.kint.2018.11.038.

PMID:
30904068
2.

International prevalence of hepatitis C positivity among hemodialysis patients awaiting transplantation.

Goodkin DA, Bieber B.

Kidney Int. 2018 May;93(5):1249. doi: 10.1016/j.kint.2018.02.009. No abstract available.

PMID:
29680026
3.

Clinical News.

Lyon S, Goodkin DA, Bronstein AM, Tatem AJ, Bown M.

Br J Hosp Med (Lond). 2017 Jan 2;78(1):8-11. doi: 10.12968/hmed.2017.78.1.8. No abstract available.

PMID:
28067555
4.

Mortality, Hospitalization, and Quality of Life among Patients with Hepatitis C Infection on Hemodialysis.

Goodkin DA, Bieber B, Jadoul M, Martin P, Kanda E, Pisoni RL.

Clin J Am Soc Nephrol. 2017 Feb 7;12(2):287-297. doi: 10.2215/CJN.07940716. Epub 2016 Dec 1.

5.

Hemodialysis patients with hepatitis C infection are not receiving the new antiviral medications.

Goodkin DA, Bieber B.

Am J Nephrol. 2015;41(4-5):302. doi: 10.1159/000432408. Epub 2015 Jun 3. No abstract available.

6.

Intravenous iron dose and mortality in hemodialysis patients.

Goodkin DA, Bailie GR.

Kidney Int. 2015 Jun;87(6):1261-2. doi: 10.1038/ki.2015.82. No abstract available.

PMID:
26024036
7.

Intravenous iron, inflammation, and ventricular dysfunction during hemodialysis.

Goodkin DA, Bailie GR.

Am J Kidney Dis. 2015 Mar;65(3):518. doi: 10.1053/j.ajkd.2014.09.030. No abstract available.

PMID:
25704045
8.

Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality.

Bailie GR, Larkina M, Goodkin DA, Li Y, Pisoni RL, Bieber B, Mason N, Tong L, Locatelli F, Marshall MR, Inaba M, Robinson BM.

Kidney Int. 2015 Jan;87(1):162-8. doi: 10.1038/ki.2014.275. Epub 2014 Jul 30.

9.

Potassium-binding resins: Associations with serum chemistries and interdialytic weight gain in hemodialysis patients.

Jadoul M, Karaboyas A, Goodkin DA, Tentori F, Li Y, Labriola L, Robinson BM.

Am J Nephrol. 2014;39(3):252-9. doi: 10.1159/000360094. Epub 2014 Mar 8.

10.

Hepatitis C infection is very rarely treated among hemodialysis patients.

Goodkin DA, Bieber B, Gillespie B, Robinson BM, Jadoul M.

Am J Nephrol. 2013;38(5):405-12. doi: 10.1159/000355615. Epub 2013 Oct 29.

PMID:
24192505
11.

Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Bailie GR, Larkina M, Goodkin DA, Li Y, Pisoni RL, Bieber B, Mason N, Tong L, Locatelli F, Marshall MR, Inaba M, Robinson BM.

Nephrol Dial Transplant. 2013 Oct;28(10):2570-9. doi: 10.1093/ndt/gft062.

PMID:
24078642
12.

Fistula versus catheter outcomes: the importance of surgical training.

Goodkin DA, Robinson BM.

Kidney Int. 2013 Mar;83(3):531-2. doi: 10.1038/ki.2012.472. No abstract available.

13.

High-dose intravenous epoetin does not increase blood pressure in critically ill patients with acute kidney injury.

Ralib AM, Pickering JW, Major T, Palmer SC, Shaw GM, Goodkin DA, Endre ZH.

Clin Nephrol. 2013 May;79(5):370-9. doi: 10.5414/CN107673.

PMID:
23320967
14.

Blood pressure levels and mortality risk among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study.

Robinson BM, Tong L, Zhang J, Wolfe RA, Goodkin DA, Greenwood RN, Kerr PG, Morgenstern H, Li Y, Pisoni RL, Saran R, Tentori F, Akizawa T, Fukuhara S, Port FK.

Kidney Int. 2012 Sep;82(5):570-80. doi: 10.1038/ki.2012.136. Epub 2012 Jun 20.

15.

Absence of anemia in hemodialysis patients.

Goodkin DA, Fuller DS, Robinson BM, Pisoni RL.

Blood Purif. 2011;32(3):209. doi: 10.1159/000328932. Epub 2011 Jul 29. No abstract available.

PMID:
21811069
16.

Iron and calciphylaxis.

Goodkin DA, Larkina M, Robinson BM.

Nephrol Dial Transplant. 2011 Sep;26(9):3063; author reply 3063-4. doi: 10.1093/ndt/gfr330. Epub 2011 Jul 12. No abstract available.

PMID:
21750156
17.

Peak oxygen uptake in ESRD.

Goodkin DA, Stray-Gundersen J.

Am J Kidney Dis. 2011 May;57(5):803. doi: 10.1053/j.ajkd.2011.03.004. No abstract available.

PMID:
21496727
18.

Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients.

Goodkin DA, Fuller DS, Robinson BM, Combe C, Fluck R, Mendelssohn D, Akizawa T, Pisoni RL, Port FK.

J Am Soc Nephrol. 2011 Feb;22(2):358-65. doi: 10.1681/ASN.2010020173. Epub 2010 Dec 16.

19.

Hemodialysis vascular access training and practices are key to improved access outcomes.

Goodkin DA, Pisoni RL, Locatelli F, Port FK, Saran R.

Am J Kidney Dis. 2010 Dec;56(6):1032-42. doi: 10.1053/j.ajkd.2010.08.010. Epub 2010 Oct 20. Review.

PMID:
20961676
20.

Independent and joint associations of nutritional status indicators with mortality risk among chronic hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Lopes AA, Bragg-Gresham JL, Elder SJ, Ginsberg N, Goodkin DA, Pifer T, Lameire N, Marshall MR, Asano Y, Akizawa T, Pisoni RL, Young EW, Port FK.

J Ren Nutr. 2010 Jul;20(4):224-34. doi: 10.1053/j.jrn.2009.10.002. Epub 2010 Jan 8.

PMID:
20060319
21.

Urinalysis in ethylene glycol poisoning.

Goodkin DA.

Am J Kidney Dis. 2009 Oct;54(4):780. doi: 10.1053/j.ajkd.2009.06.042. No abstract available.

PMID:
19781453
22.

The normal hematocrit cardiac trial revisited.

Goodkin DA.

Semin Dial. 2009 Sep-Oct;22(5):495-502. doi: 10.1111/j.1525-139X.2009.00620.x. Epub 2009 Jul 24.

PMID:
19650856
23.

The burden of amputation among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Combe C, Albert JM, Bragg-Gresham JL, Andreucci VE, Disney A, Fukuhara S, Goodkin DA, Gillespie BW, Saito A, Jadoul M, Pisoni RL.

Am J Kidney Dis. 2009 Oct;54(4):680-92. doi: 10.1053/j.ajkd.2009.04.035. Epub 2009 Jul 19.

PMID:
19619923
24.

Rosiglitazone is associated with mortality in chronic hemodialysis patients.

Ramirez SP, Albert JM, Blayney MJ, Tentori F, Goodkin DA, Wolfe RA, Young EW, Bailie GR, Pisoni RL, Port FK.

J Am Soc Nephrol. 2009 May;20(5):1094-101. doi: 10.1681/ASN.2008060579. Epub 2009 Apr 8.

25.

Enhanced training in vascular access creation predicts arteriovenous fistula placement and patency in hemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study.

Saran R, Elder SJ, Goodkin DA, Akiba T, Ethier J, Rayner HC, Saito A, Young EW, Gillespie BW, Merion RM, Pisoni RL.

Ann Surg. 2008 May;247(5):885-91. doi: 10.1097/SLA.0b013e31816c4044.

PMID:
18438128
26.

The normal hematocrit study--follow-up.

Besarab A, Goodkin DA, Nissenson AR; Normal Hematocrit Cardiac Trial Authors.

N Engl J Med. 2008 Jan 24;358(4):433-4. doi: 10.1056/NEJMc076523. No abstract available.

PMID:
18216370
27.

Burial at sea.

Goodkin DA.

Pharos Alpha Omega Alpha Honor Med Soc. 2007 Autumn;70(4):28-9. No abstract available.

PMID:
18078153
28.

Factors associated with health-related quality of life among hemodialysis patients in the DOPPS.

Lopes AA, Bragg-Gresham JL, Goodkin DA, Fukuhara S, Mapes DL, Young EW, Gillespie BW, Akizawa T, Greenwood RN, Andreucci VE, Akiba T, Held PJ, Port FK.

Qual Life Res. 2007 May;16(4):545-57. Epub 2007 Feb 8. Erratum in: Qual Life Res. 2007 Aug;16(6):1095.

PMID:
17286199
29.

Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.

Herndon RM, Rudick RA, Munschauer FE 3rd, Mass MK, Salazar AM, Coats ME, Labutta R, Richert JR, Cohan SL, Genain C, Goodkin D, Toal M, Riester K.

Mult Scler. 2005 Aug;11(4):409-19.

PMID:
16042223
30.

Kidney transplantation and wait-listing rates from the international Dialysis Outcomes and Practice Patterns Study (DOPPS).

Satayathum S, Pisoni RL, McCullough KP, Merion RM, Wikström B, Levin N, Chen K, Wolfe RA, Goodkin DA, Piera L, Asano Y, Kurokawa K, Fukuhara S, Held PJ, Port FK.

Kidney Int. 2005 Jul;68(1):330-7.

31.

Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study.

Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK.

Kidney Int. 2005 Mar;67(3):1179-87.

32.

Mortality among hemodialysis patients in Europe, Japan, and the United States: case-mix effects.

Goodkin DA, Young EW, Kurokawa K, Prütz KG, Levin NW.

Am J Kidney Dis. 2004 Nov;44(5 Suppl 2):16-21.

PMID:
15486869
33.

Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Bommer J, Locatelli F, Satayathum S, Keen ML, Goodkin DA, Saito A, Akiba T, Port FK, Young EW.

Am J Kidney Dis. 2004 Oct;44(4):661-71.

PMID:
15384017
34.

International variation in vitamin prescription and association with mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Fissell RB, Bragg-Gresham JL, Gillespie BW, Goodkin DA, Bommer J, Saito A, Akiba T, Port FK, Young EW.

Am J Kidney Dis. 2004 Aug;44(2):293-9.

PMID:
15264188
35.

Mitoxantrone as a potential therapy for primary progressive multiple sclerosis.

Stüve O, Kita M, Pelletier D, Fox RJ, Stone J, Goodkin DE, Zamvil SS.

Mult Scler. 2004 Jun;10 Suppl 1:S58-61. Review.

PMID:
15218811
36.

Prospective study of the immune effects of normalizing the hemoglobin concentration in hemodialysis patients who receive recombinant human erythropoietin.

Roman RM, Lobo PI, Taylor RP, Goodkin DA, LaBrecque J, Powers KL, Bolton WK.

J Am Soc Nephrol. 2004 May;15(5):1339-46.

37.

Mortality and hospitalization in haemodialysis patients in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Rayner HC, Pisoni RL, Bommer J, Canaud B, Hecking E, Locatelli F, Piera L, Bragg-Gresham JL, Feldman HI, Goodkin DA, Gillespie B, Wolfe RA, Held PJ, Port FK.

Nephrol Dial Transplant. 2004 Jan;19(1):108-20.

PMID:
14671046
38.

Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Goodkin DA, Bragg-Gresham JL, Koenig KG, Wolfe RA, Akiba T, Andreucci VE, Saito A, Rayner HC, Kurokawa K, Port FK, Held PJ, Young EW.

J Am Soc Nephrol. 2003 Dec;14(12):3270-7.

39.

Brain lesion volume and neuropsychological function predict efficacy of treatment for depression in multiple sclerosis.

Mohr DC, Epstein L, Luks TL, Goodkin D, Cox D, Goldberg A, Chin C, Nelson S.

J Consult Clin Psychol. 2003 Dec;71(6):1017-24.

PMID:
14622077
40.

Therapy-related leukemia in mitozantrone treated patients.

Goodkin DE.

Mult Scler. 2003 Aug;9(4):426. No abstract available.

PMID:
12926850
41.

Venous access: are women equal?

Goodkin DA, Port FK.

Am J Kidney Dis. 2003 Aug;42(2):428; author reply 429. No abstract available.

PMID:
12900830
42.

MRI lesion volume heterogeneity in primary progressive MS in relation with axonal damage and brain atrophy.

Pelletier D, Nelson SJ, Oh J, Antel JP, Kita M, Zamvil SS, Goodkin DE.

J Neurol Neurosurg Psychiatry. 2003 Jul;74(7):950-2.

43.

Health-related quality of life as a predictor of mortality and hospitalization: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Mapes DL, Lopes AA, Satayathum S, McCullough KP, Goodkin DA, Locatelli F, Fukuhara S, Young EW, Kurokawa K, Saito A, Bommer J, Wolfe RA, Held PJ, Port FK.

Kidney Int. 2003 Jul;64(1):339-49.

44.

Nonadherence in hemodialysis: associations with mortality, hospitalization, and practice patterns in the DOPPS.

Saran R, Bragg-Gresham JL, Rayner HC, Goodkin DA, Keen ML, Van Dijk PC, Kurokawa K, Piera L, Saito A, Fukuhara S, Young EW, Held PJ, Port FK.

Kidney Int. 2003 Jul;64(1):254-62.

46.

Health-related quality of life and associated outcomes among hemodialysis patients of different ethnicities in the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Lopes AA, Bragg-Gresham JL, Satayathum S, McCullough K, Pifer T, Goodkin DA, Mapes DL, Young EW, Wolfe RA, Held PJ, Port FK; Worldwide Dialysis Outcomes and Practice Patterns Study Committee.

Am J Kidney Dis. 2003 Mar;41(3):605-15.

PMID:
12612984
47.

Pharmacologic and cytokine treatment of commonly encountered anemias.

Foote M, Colowick A, Goodkin DA.

Cytokines Cell Mol Ther. 2002 Dec;7(2):49-59. Review.

PMID:
12607795
48.

T2 relaxation time histograms in multiple sclerosis.

Grenier D, Pelletier D, Normandeau M, Newitt D, Nelson S, Goodkin DE, Majumdar S.

Magn Reson Imaging. 2002 Dec;20(10):733-41.

PMID:
12591569
49.

IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS.

Waubant E, Goodkin D, Bostrom A, Bacchetti P, Hietpas J, Lindberg R, Leppert D.

Neurology. 2003 Jan 14;60(1):52-7.

PMID:
12525717
50.

Creation, cannulation and survival of arteriovenous fistulae: data from the Dialysis Outcomes and Practice Patterns Study.

Rayner HC, Pisoni RL, Gillespie BW, Goodkin DA, Akiba T, Akizawa T, Saito A, Young EW, Port FK; Dialysis Outcomes and Practice Patterns Study.

Kidney Int. 2003 Jan;63(1):323-30.

Supplemental Content

Loading ...
Support Center